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ARTICLE
Myoblasts and macrophages are required for
therapeutic morpholino antisense oligonucleotide
delivery to dystrophic muscle
James S. Novak1,2,3, Marshall W. Hogarth1, Jessica F. Boehler1,2, Marie Nearing1, Maria C. Vila1,2, Raul Heredia1,
Alyson A. Fiorillo1,2,3, Aiping Zhang1, Yetrib Hathout1,2,3,4, Eric P. Hoffman1,2,3,4, Jyoti K. Jaiswal 1,2,3,
Kanneboyina Nagaraju1,2,3,4, Sebahattin Cirak1,5,6,7 & Terence A. Partridge1,2,3
Exon skipping is a promising therapeutic strategy for Duchenne muscular dystrophy (DMD),
employing morpholino antisense oligonucleotides (PMO-AO) to exclude disruptive exons
from the mutant DMD transcript and elicit production of truncated dystrophin protein. Clinical
trials for PMO show variable and sporadic dystrophin rescue. Here, we show that robust
PMO uptake and efficient production of dystrophin following PMO administration coincide
with areas of myofiber regeneration and inflammation. PMO localization is sustained in
inflammatory foci where it enters macrophages, actively differentiating myoblasts and newly
forming myotubes. We conclude that efficient PMO delivery into muscle requires two
concomitant events: first, accumulation and retention of PMO within inflammatory foci
associated with dystrophic lesions, and second, fusion of PMO-loaded myoblasts into
repairing myofibers. Identification of these factors accounts for the variability in clinical trials
and suggests strategies to improve this therapeutic approach to DMD.
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Duchenne muscular dystrophy (DMD) is a severe andrelentlessly progressive myopathy that results fromout-of-frame or nonsense mutations in the X-linked
DMD gene that disrupt the mRNA open reading frame and
prevent translation of dystrophin protein1, 2. In DMD patients,
the lack of dystrophin leads to persistent muscle degeneration,
inflammation, and fibrosis, with associated loss of myofiber
structural integrity and functional strength3. The milder, allelic
variant, Becker muscular dystrophy (BMD) results from in-frame
mutations in the DMD gene that permit expression of an
internally truncated, partially functional dystrophin isoform4, 5.
This understanding has inspired a therapeutic strategy in which
antisense oligonucleotides (AO) are designed to restore the open
reading frame by excluding disruptive exons so as to permit
translation of a truncated dystrophin protein6–9, thus converting
DMD to a milder BMD phenotype4, 5. Preclinical testing of
AOs favors the phosphorodiamidate morpholino oligomers
(morpholino, PMO) on the basis both of efficacy of exon skipping
and dystrophin restoration and of low toxicity10–19. Despite its
promise for DMD, the path through clinical trials to FDA
approval has been complicated by the technical challenges of
accurate measurement of the variable and patchy distribution of
restored dystrophin in the context of the ethical limitations on
dystrophic muscle biopsies as clinical endpoint measures20–24.
Our recent investigations found no evidence of association
between exon skipping efficacy and residual PMO concentrations
within muscles, or the preference of systematically delivered
PMO for particular muscle groups or fiber types, suggesting
the existence of other constraints25. Following IV injection,
PMO remained detectible in the serum for less than 2 h (half-life
~30 min), while the majority accumulated in the liver and kidneys
or was excreted in the urine26–28. Meanwhile, trace amounts of
PMO were found distributed throughout the muscle, where it
diminished slowly throughout the first week. The resulting
pharmacokinetic picture is of rapid elimination of even high
concentrations of PMO from the bloodstream, and limited entry
into muscle fibers that, together, severely restrict its availability to
myonuclei where it exerts its biological activity26–28.
To elucidate the factors that influence the efficacy of exon
skipping in preclinical studies and clinical trials, we have traced
the route of PMO delivery into nuclei of regenerating muscle in
the dystrophic mdx mouse model. To identify the “birthdate” of
myogenic cells in regenerating muscle lesions in mdx mice, we
used 3 day phases of bromodeoxyuridine (BrdU) administration
staggered relative to a single intravenous dose of PMO. This
defined a narrow “window of opportunity” in which PMO is able
to efficiently penetrate differentiating myoblasts and actively
repairing myofibers to yield productive exon skipping and
dystrophin expression. These newly identified pathophysiological
features trigger a fundamental revision of the pharmacokinetics
underlying the distribution of PMO-induced exon skipping
for DMD and highlight new targets for improvement of this
therapeutic strategy.
Results
Myofiber “birthdating” strategy to investigate PMO delivery.
Our investigation was guided by two earlier observations: (1) a
general correlation of PMO entry with muscle fiber damage29
and (2) patchy distribution of dystrophin expression produced by
systemic delivery of PMO that echoes the pattern of DMD/mdx
muscle lesions25, 30 (Fig. 1a). We chose to simplify interpretation
of our experiments by concentrating on the first round of
spontaneous lesions that appear in muscles of the mdx mouse
beginning at ~21 days of age31–33. A single, high intravenous dose
of PMO was administered on postnatal day 28 and BrdU was
provided ad libitum in the drinking water over the 3 day periods
from 21 to 24 days, 24 to 27 days, or 28 to 31 days of age (Fig. 1b).
We first confirmed a previous observation that BrdU admin-
istration in wild-type mice of this same age, labeled only sporadic
cells lying between muscle fibers but not myonuclei34 (Fig. 1c). In
contrast, age-matched mdx mice exhibited conspicuous scattered
patches of labeling throughout the muscle; these comprised both
BrdU-labeled myonuclei, indicating newly regenerated myofibers,
and interstitial cells, largely denoting proliferating inflammatory
cells (Fig. 1c). Observations over the first few days of BrdU
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Fig. 1 PMO and BrdU co-administration to investigate PMO uptake and
efficacy relative to regeneration. a Patchy dystrophin expression shown in
mdx quadriceps 2 weeks after single IV dose of PMO (800mg/kg, n= 3).
Dashed box shows magnified inlay, scale bars represent 100 μm. b Schematic
representation of parallel PMO-BrdU labeling assays to investigate
relationship between PMO localization, dystrophin expression, and muscle
regeneration. c Onset of mdx pathology at 4 weeks characterized by
widespread regeneration shown by BrdU labeling of centrally nucleated
fibers. Bl10 muscle without regeneration shown as control with only minor
labeling of interstitial nuclei. BrdU (green), laminin (blue), and propidium
iodide (PI, red). Scale bars represent 50 μm. d BrdU labeling of newly
regenerated fibers shown in 4 week mdx gastrocnemius 48 and 72 h
following a 24 h feeding of BrdU. Scale bars represent 50 μm
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administration revealed the first BrdU-labeled centrally positioned
myonuclei 2 days post administration, establishing this as the
minimum transit time from S-phase through myoblast differ-
entiation and fusion (Fig. 1d). By day 3, most lesions are solidly
populated by BrdU-labeled myonuclei, indicating that the
staggered 3 day BrdU protocol is appropriate to analyze
regenerative cohorts of myogenic cells.
PMO-induced dystrophin expression specific to dystrophic
lesions. To identify the “birthdates” of myoblasts that gave rise
to dystrophin+ve fibers in vivo, BrdU was provided for staggered
72 h intervals over 21–24, 24–27, and 28–31 days of age, with respect
to a single systemic dose of PMO targeting Dmd exon 23 (800mg/kg;
5′-GGCCAAACCTCGGCTTACCTGAAAT-3′12, 35, 36) adminis-
tered on day 28 (Fig. 1b). Mice were euthanized 14 days after PMO
delivery to assess dystrophin expression in the triceps, gastrocnemius,
and quadriceps, typically high-responding muscle groups25 (Fig. 1b).
This pinpoints the stages of myoblast proliferation and fusion at
which PMO was most effectively delivered into the muscle fibers
within sites of spontaneous degeneration/regeneration.
We quantified all myofibers that labeled for dystrophin, BrdU
or both. In all mice, BrdU labeling produced sporadic patches of
central BrdU+ve nuclei within small-diameter myofibers (Fig. 1c, d).
Myofibers derived from myogenic precursor cells that had
proliferated during the 3 days prior to PMO delivery showed
markedly greater incidence of dystrophin expression than those
of the other BrdU cohorts. In the BrdU 24–27 days cohort, some
57% of fibers were double-positive for dystrophin and BrdU
(Fig. 2a, b), while 66% of all dystrophin+ve fibers contained
at least one BrdU+ve nucleus and 87% were localized within
actively regenerating foci as indicated by a predominance of
BrdU-positive myonuclei (Fig. 2c, d). By contrast, in mice given
BrdU during days 21–24, only 11% of dystrophin+ve
fibers contained a BrdU-labeled central nucleus (Fig. 2a–d).
Interestingly, BrdU administration after PMO treatment, during
days 28–31, produced co-labeling in 31% of labeled myofibers
(Fig. 2a–d), indicating some myoblast proliferation subsequent to
PMO administration. This tail end of our defined “window” of
optimal PMO uptake perhaps indicates persistence of a local
reservoir of PMO after its elimination from the blood. Absolute
numbers of BrdU-labeled fibers or dystrophin-expressing fibers
did not differ between these three dosing cohorts, indicating a
constant rate of regeneration and of PMO uptake over this time
(Supplementary Fig. 1a).
The absence of a BrdU+ve myonucleus within some
dystrophin+ve fibers, reflects, in part, the fact that within 8 µm
cross-sections many myofiber profiles do not contain a nucleus,
thus underestimating the proportion of fibers that do contain a
BrdU+ve myonucleus. In confirmation, ~90% of dystrophin+ve
fibers contained at least one BrdU-labeled central nucleus within
four adjacent serial sections along the axis of the fiber (Supple-
mentary Fig. 1b). We later found that high concentrations of
4′,6-diamidino-2-phenylindole (DAPI) would mark BrdU−ve nuclei
and confirmed that ~25% of myofiber profiles in any given cross-
section did not include a nucleus (Supplementary Fig. 1c).
Assessment of dystrophin+ve fibers in BrdU/DAPI-labeled muscles
(Fig. 2e, f) echoed our previous analysis, identifying the same
optimal 3–4 day window prior to PMO delivery.
In summary, efficient uptake of PMO on day 28 was minimal
in cells that had proliferated over the 21–24 day BrdU exposure
period, but occurred in 75% of those that proliferated between
24 and 27 days, and in 30% of those which had undertaken at
least one S-phase after exposure to PMO (Fig. 2f). These results
imply that PMO enters muscle fibers predominantly during the
final phases of regeneration.
Mechanisms of PMO entry persist in older mdx mice. To
determine whether this mechanism is limited to the initial onset
period of conspicuous pathology, we treated mature 13-week-old
mdx mice with high-dose PMO, following a 3-day administration
of BrdU. Fewer actively regenerating lesions and dystrophin-
expressing fibers were observed in these older mice, and therefore
we were easily able to count all fibers within a muscle cross-
section that were dystrophin+ve and/or contained a BrdU+ve
myonucleus. In PMO-treated mice, these counts showed a strong
bias toward dystrophin/BrdU co-labeling, where in fibers marked
by either label, ~52% were double-labeled (Fig. 3a–c), while 99%
of all BrdU+ve fibers were dystrophin+ve (Fig. 3b). Thus, almost all
fibers that had undergone regeneration during the 3 days prior to
PMO delivery had gone on to produce dystrophin. This tighter
association between exon skipping and active regeneration may
be attributable to the lower frequency of pathological episodes
in older mdx mice, lowering the incidence of BrdU labeling in
separate, temporally overlapping lesions.
Small isolated pockets of dystrophin+ve/BrdU−ve fibers were
noted in both saline and PMO-treated groups (Fig. 3c). We
interpret these as expanded clusters of “revertant” fibers typical in
the mdx mouse at this age37, 38. In saline-treated mice <1% of
these “revertant” fibers were BrdU+ve, indicating a low incidence
of active expansion as predicted in earlier studies37, 38.
Inflammatory exudation targets PMO to sites of regeneration.
More direct observations of PMO entry into muscle were
conducted with fluorescein-conjugated PMO (F-PMO), identified
by immunostaining for the fluorescein tag. After a single
intravenous dose, F-PMO was predominantly detected in muscle
regions exhibiting active regeneration associated with dense
patches of mononucleated interstitial inflammatory cells
(Supplementary Fig. 2a–d). Functional exon skipping activity of
F-PMO was confirmed through reverse transcriptase quantitative
PCR (RT-qPCR) and dystrophin immunostaining following
systemic delivery (Supplementary Fig. 3a–d). Importantly, the
slight negative charge caused by conjugation with carboxy-
fluorescein had no significant effect on exon skipping efficacy.
To confirm PMO accumulation within inflammatory/regener-
ating lesions as a key factor modulating its uptake, we assessed
intramuscular PMO and exon skipping in wild-type Bl10 mice
injected intravenously with 400 mg/kg of F-PMO and observed
only sparse interstitial distribution of the F-PMO throughout the
muscle, likely corresponding to resident macrophages. However,
no F-PMO was observed within myonuclei of muscle fibers
(Supplementary Fig. 4a). RT-qPCR revealed ~1% exon skipping,
modestly higher than the <0.1% detected in saline-treated Bl10 or
mdx muscles, but significantly below the >10% in muscles of
PMO-treated mdx mice (Supplementary Fig. 4b, c).
Staining for the macrophage marker F4/80 revealed that a
majority of PMO+ve interstitial cells within muscle lesions
correspond to infiltrating macrophages (Fig. 4a, b). These were
observed in clusters within the endomysium and perimysium
adjacent to regenerating myofibers and retained prominent
F-PMO signal after 7 days, at which time, it was largely
undetectable in myonuclei (Fig. 4b, Supplementary Fig. 5a).
PMO was also seen in approximately half of resident macro-
phages diffusely distributed throughout non-inflamed regions of
mdx and WT muscle but remained undetectable in myonuclei in
these situations (Fig. 4c, d). Together, these observations suggest
that this class of inflammatory cell is strongly predisposed
to PMO uptake, perhaps through phagocytic mechanisms.
The compact distribution of PMO within lesions strongly
suggests that inflammatory exudation from the blood is
responsible for PMO accumulation at specific sites within the
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Fig. 2 Systemic PMO delivery targets dystrophin expression to spontaneously regenerating mdx myofibers. a Dystrophin expression in 6 week mdx mice
(i.e., tricep, gastrocnemius, and quadriceps) after single IV dose of PMO (800mg/kg, n= 3). PMO injected at day 28 together with staggered pulses of
BrdU (i.e., 21–24 days, 24–27 days, 28–31 days). Dystrophin (Dys, red) and BrdU+ve myonuclei (green) 14 days after PMO. Venn diagrams demonstrate the
overlap between dystrophin expression (Dys+ve) and myofiber regeneration (BrdU+ve). b Quantification of Dys+ve/BrdU+ve, Dys+ve/BrdU−ve, and Dys−ve/
BrdU+ve myofibers for each BrdU cohort shown as a percentage of labeled fibers. Data represented as scatter plot with SD; n= 3 mdxmice per BrdU cohort.
c Quantification of total fibers characterized as Dys+ve/BrdU+ve (red), Dys+ve/BrdU−ve within a regenerating lesion (dashed red), Dys+ve/BrdU−ve isolated
revertants (blue), or Dys−ve/BrdU+ve (gray). d Quantification of BrdU co-localization in dystrophin+ve fibers; Dys+ve/BrdU+ve (red), Dys+ve/BrdU−ve within a
regenerating lesion (dashed red), Dys+ve/BrdU−ve (blue) (n= 3). e BrdU-DAPI co-staining procedure to confirm BrdU specificity and assess prevalence of
central myonuclei per myofiber within a given cross-section. f Quantification of BrdU-labeling for centrally nucleated (DAPI+ve), dystrophin+ve myofibers.
Scale bars represent 100 μm. Statistical analysis performed by Mann–Whitney nonparametric test; ***p< 0.001, **p< 0.01, *p< 0.05
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muscle where it is retained long after the agent has been cleared
from the systemic circulation27.
PMO distribution parallels localization of dystrophin expres-
sion. Our previous investigations of mdx muscle had found no
correlation between mature fast or slow-twitch fiber types and the
level of dystrophin restoration25, while acute cardiotoxin-induced
muscle injury showed facilitated entry of PMO into regenerating
fibers expressing embryonic myosin heavy chain (MYH3)—in
both C57Bl/6 wild-type and mdx52 dystrophin-null mice29. Here,
we detected PMO for some 7 days after systemic administration
where it was observed diffusely localized within interstitial
spaces at scattered sites of inflammation and regeneration
(Supplementary Fig. 2d), and was associated both with small-
diameter, centrally nucleated, MYH3+ve myofibers and mono-
nucleated interstitial cells (Fig. 5a, b, Supplementary Fig. 5a, b).
Fibers that were MYH3+ve but lacked detectible PMO fell into
two classes: those that did not contain a central nucleus within
that given cross-section and those of larger diameter, suggesting
that they had fully regenerated, but not fully matured, prior to
PMO administration (Fig. 5b). Our general conclusion that
PMO directly entered mononucleated cells, but not mature,
multinucleated myofibers is subject to one exception; myonuclei
of some spindle fibers located within regenerating lesions
contained PMO but were not BrdU-positive. This was observed in
spindle fibers residing in pathological lesions (Supplementary
Fig. 5c, d). The thick capsule surrounding spindle fiber bundles
does not commend them as obvious candidates for PMO
penetration, thus we must look to some other quality that makes
them uniquely susceptible to PMO uptake.
Direct observation of PMO uptake was conducted on a second,
parallel BrdU timing assay, employing F-PMO to permit precise
histological localization. F-PMO (400 mg/kg) was injected into
28-day-old mdx mice in conjunction with 3-day BrdU treatments
staggered from days 21–24, 24–27, and 28–31, with euthanasia on
day 32 for immunofluorescent detection of residual F-PMO
(Fig. 1b). Incompatibility of the immunostaining procedures for
BrdU and PMO detection prevented direct co-localization and
required comparison between serial cross-sections. Within
regions of robust PMO localization of entire cross-sections of
the gastrocnemius, triceps, and quadriceps, we assessed BrdU and
PMO incorporation within individual fibers that could be tracked
between adjacent serial sections. PMO and BrdU co-localized
within nuclei exclusively within areas of regeneration and
inflammation. Small-diameter, PMO/BrdU co-labeled myonuclei
predominated in the two BrdU treatment cohorts adjacent to
PMO delivery: ~76% in the 24–27 day BrdU cohort, and ~60% of
fibers in the 28–31 day BrdU cohort (Fig. 6a, b). In contrast, in
the 21–24 day BrdU cohort only 7% of fibers in PMO-enriched
regions were PMO+ve/BrdU+ve, indicating poor PMO entry into
fully formed myofibers (Fig. 6a, b).
The observation of PMO+ve/BrdU+ve myonuclei in the 28–31-
day treatment cohort indicates that some cells had undergone
proliferation after exposure to PMO; this is intriguing in light of
the short, <1 h half-life of PMO in the serum25, 27, 28, since it
suggests that PMO is available for entry into regenerating
myotubes for considerably longer than it is detectable in the
serum. It is also possible that PMO had entered those myoblasts
prior to the last cell cycle before terminal differentiation. These
are not exclusive alternatives but the fact that residual PMO levels
remained visually detectible within muscle lesions over this
period inclines us toward the former explanation.
PMO enters muscle precursor cells in dystrophic lesions. We
observed high incidence of PMO in mononucleated cells within
inflammatory lesions for several days following systemic delivery of
the tagged-PMO (400mg/kg, single dose), many of which
co-stained with the macrophage marker F4/80. However, significant
numbers of PMO+ve nuclei co-stained for paired box 7 protein
(PAX7) or myogenic factor 4 (MYOG) (Fig. 7a, Supplementary
Fig. 6), markers of satellite cell status and terminal myoblast
differentiation, respectively (Fig. 7c). Meanwhile, quiescent, PAX7-
expressing satellite cells residing at sites remote from muscle lesions
contained no detectable PMO (Fig. 7b). Together, these results
suggest that the robust uptake of PMO by myogenic precursor cells
occurs exclusively within regenerating lesions, perhaps a reflection
of the membrane changes associated with differentiation and fusion
of myogenic cells together with the high local concentrations of
PMO maintained within inflammatory lesions. This implicates
myogenic precursor cells as integral mediators of PMO uptake into
myofibers undergoing active repair.
PMO uptake is augmented during myoblast differentiation
and fusion. Further investigations of the relationship between
myoblast differentiation and fusion on PMO uptake and exon
skipping were conducted in vitro. H2k-mdx myoblasts were
maintained in 100 μM F-PMO for 24 h periods during
proliferation and over the course of differentiation. In conditions
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Fig. 3 PMO entry of regenerating myofibers in mature mdx mice.
a Dystrophin expression specific to BrdU+ve regenerated myofibers in aged
mdx muscle (triceps, gastrocnemius, and quadriceps) following a single IV
dose of PMO (800mg/kg, n= 3) at 13 weeks of age in conjunction with
BrdU administered for 72 h prior to PMO delivery. Dystrophin expression
(Dys, red) and BrdU+ve central myonuclei (green) 14 day after PMO to
evaluate dystrophin restoration relative to muscle regeneration. Venn
diagram demonstrates the overlap between dystrophin expression (Dys+ve)
and myofiber regeneration (BrdU+ve). Scale bar represents 100 μm.
b Quantification of Dys+ve/BrdU+ve, Dys+ve/BrdU−ve, and Dys−ve/BrdU+ve
myofibers shown as a percentage of labeled fibers. Data represented as
scatter plot with SD. c Quantification of labeled fibers classified as
Dys+ve/BrdU+ve (red), Dys+ve/BrdU−ve within a regenerating lesion (dashed
red), Dys+ve/BrdU−ve (blue), or Dys−ve/BrdU+ve (gray) (n= 4). Statistical
analysis performed by Mann–Whitney nonparametric test; ***p< 0.001
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permissive of active SV40 large T antigen, these cells proliferate,
but when moved to non-permissive conditions (37 °C without
IFNγ), switch rapidly to differentiation39. To mimic in vivo
conditions, we used PMO concentrations calculated to corre-
spond to the systemic concentrations immediately after IV
delivery, assuming that these would be close to equilibrium with
those within the inflammatory microenvironment of regenerating
muscle foci (Supplementary Fig. 7a). Immunostaining for F-PMO
revealed no significant uptake by proliferating myoblasts;
however, onset of differentiation elicited a rapid intracellular
uptake of PMO over the first 3 days of differentiation (Fig. 8a, b),
amounting to a greater than 6-fold increase between proliferating
and 3-day-differentiated cells (Fig. 8b). The abrupt drop in
intracellular PMO on days 4–5, we attribute largely to the artifacts
of detachment and fragility of myotubes at this stage (Fig. 8b).
Exon skipping efficiency, monitored by RT-qPCR across this
period, peaked between 2–5 days post-differentiation at nearly
60% skipped vs. full-length (Fig. 8c). At full differentiation, we
noted the proportion of skipped Dmd transcript rose with
duration of PMO exposure (i.e., 24 h compared to 3 h) (Fig. 8c).
Myogenic differentiation was confirmed by Western blot for
embryonic myosin (MYH3), which appeared at +1 day and
peaked at +3 day (Supplementary Fig. 7c). We also examined the
effect of prolonged PMO exposure on actively fusing myotubes, a
scenario paralleling that in regenerating lesions in vivo, treating
myotubes 3 days after onset of differentiation for 72 h with
50–500 μM PMO. We found that prolonged PMO exposure
masked any significant effect of PMO dosage on exon skipping in
culture (Supplementary Fig. 7b), identifying exposure time as a
major factor in efficiency of exon skipping.
To further investigate the individual impacts of myoblast
differentiation and fusion on uptake of PMO, we took advantage
of the density-dependence of fusion efficiency to modulate myoblast
fusion without pharmacological interference. Seeding density for
optimal fusion (26,000 cells/cm2) was reduced by 75% to 6500 cells/
cm2, thus preventing fusion under differentiation conditions
(Fig. 8d). Two days after switching to non-permissive conditions,
which corresponds to the peak of myoblast fusion under our
optimal seeding conditions, cultures were treated with F-PMO (100
μM, 24 h). Differentiation was monitored by measuring Desmin
(Des) and embryonic myosin (Myh3) mRNA transcript levels
(Supplementary Fig. 7d, e). In our low-density, differentiating, non-
fused myoblasts, intracellular F-PMO rose by ~2-fold over
proliferating, undifferentiated myoblasts (Fig. 8b, e), but further
increased to ~4-fold in fusing myoblast cultures (Fig. 8e). Thus,
myoblast differentiation and fusion each contribute individually to
efficient PMO uptake. This supports the idea that PMO is delivered
into fusing myotubes both by PMO-loaded differentiating myo-
blasts and during the process of fusion itself.
Assessment of exon skipping by quantifying copy number of
Dmd 22–24 skipped relative to non-skipped transcript showed the
same percent exon skipping, but revealed a significant increase in
overall Dmd transcript copy number accompanying active
myoblast fusion (Fig. 8f). Thus, the higher concentrations of
PMO in cultured myotubes does not increase the percentage of
exon skipping but does boost overall dystrophin transcription
rate thus generating a greater total yield of skipped transcript. We
conclude that (1) myoblast differentiation is sufficient to promote
enhanced PMO uptake independently of myotube formation, and
(2) concurrent myoblast differentiation and fusion promote
robust PMO uptake through fusion of PMO-loaded myogenic
cells during formation and by the myofiber repair process itself.
PMO uptake by macrophages provides sustained PMO release
in culture. Much of the in vivo PMO accumulation in inflam-
matory foci is located within infiltrating macrophages, identifying
them as a potential PMO repository within dystrophic lesions.
When tested in vitro, RAW 264.7 macrophages treated for 24 h
a
Infiltrating macrophages Resident macrophages
Bl10mdx mdxmdx c db
F-PMO WGA DAPI F-PMO WGA DAPI F-PMO WGA DAPI F-PMO WGA DAPI
Mϕ WGA DAPI Mϕ WGA DAPIMϕ WGA DAPIMϕ WGA DAPI
F-PMO Mϕ WGA DAPIF-PMO Mϕ  WGA DAPIF-PMO Mϕ WGA DAPIF-PMO Mϕ WGA DAPI
Fig. 4 PMO penetrates infiltrating inflammatory cells targeting regions of active muscle regeneration. a PMO uptake within infiltrating macrophages,
targeting areas of regeneration after systemic F-PMO delivery in 4 week mdx mice (400mg/kg, n= 3); PMO uptake observed within myonuclei is marked
by arrow, while PMO-loaded macrophages (Mφ) are marked by arrowheads and immunostained with F4/80. b Widespread PMO accumulation within a
large population of infiltrating macrophages and other inflammatory cells targeting degenerating myofibers. c, d Sporadic PMO uptake within interstitial,
resident macrophages localized in non-regenerating mdx (c) and wild-type (d) muscle. Arrowheads mark examples of PMO+ve macrophages. Muscles were
analyzed following single injection of F-PMO, mice were euthanized 4 days post-PMO delivery. PMO, red; macrophage F4/80, green; DAPI, blue; WGA,
white; scale bars represent 10 μm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00924-7
6 NATURE COMMUNICATIONS |8:  941 |DOI: 10.1038/s41467-017-00924-7 |www.nature.com/naturecommunications
with 10–250 μM F-PMO showed robust uptake (Fig. 9a). Con-
centrations of 100 or 250 μM F-PMO produced a total intracellular
F-PMO content of ~28 or ~65 pmol per cell pellet, respectively,
even after the 3 days of proliferation in the absence of F-PMO
(Fig. 9b). Cultured macrophages (3 × 106), each with an approx-
imate volume of 103 µl, thus contained an estimated intracellular
store of 8.6 and 19.8 μM, respectively (Supplementary Fig. 8a).
Next, we sought to test our hypothesis that release of PMO
from macrophages may allow enhanced and prolonged PMO
delivery to differentiating myoblasts in vivo. Macrophages were
treated for 24 h with F-PMO (0, 10, 100, and 250 μM) then moved
to fresh medium and aliquots were taken at 30min, 24 h, 48 h, and
72 h to monitor the progressive accumulation of
F-PMO released into the medium. Over 72 h, macrophages
treated with an initial concentration of 100 or 250 μM F-PMO,
released a total of 40 and 111 pmol F-PMO per culture well,
corresponding to concentrations of 32 and 88 nM F-PMO,
respectively, into the culture media (Fig. 9c, Supplementary
Fig. 8b). Cell viability assay, by CCK-8 and trypan blue exclusion,
24, 48, and 72 h after removal of PMO, showed no evidence
of accompanying cell death (Fig. 9d). We conclude that
macrophages take up significant quantities of PMO, and
subsequently release some 60% of their initial content over 72 h
(Fig. 9b, c). This accords well with the idea that macrophages
generate a reservoir of PMO at sites of muscle regeneration, which
may subsequently be released intact in the vicinity of regenerating
myotubes, thus extending the period of exposure of regenerating
myofibers to PMO, long after it has disappeared from the serum.
Repeat PMO delivery targets regenerating foci to increase
dystrophin. Our protocol of a single, high dose of PMO was
designed specifically to elucidate the relationship between
PMO entry and muscle pathology, but current PMO clinical
studies employ repeated low-dose regimens. A conservative
dose-by-factor approach to between-species translation40 equates
a 20 mg/kg dose in humans to ~200 mg/kg in mice. Systemic
injection of low-dose PMO (200 mg/kg) into 4–6-week-old mdx
mice, both as a single dose and as four doses given at weekly
intervals, was compared to a single high-dose (800 mg/kg)
treatment. For both single-dose regimens, BrdU was given during
the 3 days prior to PMO administration. This resulted in the same
frequencies of dystrophin and BrdU co-labeling as in previous
experiments, with some 60–65% of dystrophin-expressing fibers
containing BrdU-labeled central nuclei, indicative of active
regeneration prior to PMO delivery (Fig. 10a, b).
The single low-dose PMO administration produced signifi-
cantly fewer dystrophin+ve fibers (5.6%) than four weekly
low-dose injections (8.9%), or the single high-dose PMO
administration (9.1%) (Fig. 10c). Intriguingly, the effects of four
weekly doses were not additive, resulting in only a doubling,
rather than the expected quadrupling, of the number of
dystrophin-expressing fibers, suggesting either turnover of those
fibers or of the protein and/or a fluctuating rate of regeneration
over the extended time frame. We conclude that the extent of
muscle regeneration and associated inflammation at the time of
systemic PMO delivery dictate both drug delivery and pharma-
codynamics within individual muscles, and thus have direct
implications for current PMO clinical trials where increasing both
dose and frequency of delivery could have profound benefits.
Discussion
A plausible antisense therapy for DMD must deliver functionally
effective amounts of the therapeutic agent to a substantial
proportion of myonuclei within large muscle groups distributed
throughout the body, a target that can be reached comprehen-
sively only by way of the blood vascular system. Currently the
mechanisms regulating transfer of morpholino antisense from
blood into cells, and the factors influencing their access to and
interaction with the nascent dystrophin transcript are poorly
understood. Furthermore, up to now, the basis of the pattern of
dystrophin expression achieved through intravenous delivery of
PMO in both preclinical and clinical investigations has defied
elucidation25. For human exon skipping trials with ethical
limitations on patient biopsy sampling, the resulting sparse
Poisson distribution of the data has complicated interpretation24.
It has long been clear that effective PMO-induced exon
skipping is dependent on some pathological aspect of the genetic
defect and has been associated with pathological processes29;
however, the precise cellular mechanisms have not previously been
definitively identified and the notion that PMO entry is associated
with a generalized “leakiness” of the dystrophic muscle fiber
membrane is widely promulgated. Here, we have focused on the
cellular and pathological mechanisms that impinge on delivery of
PMO antisense into muscle fibers, which has been shown to
F-PMO 400 mg/kg


















































PMO uptake in MYH3-expressing fibers
**
Fig. 5 PMO uptake prevalent among actively regenerating myofibers
expressing embryonic myosin heavy chain. a PMO localization and uptake
specific to regenerating myofiber clusters expressing MYH3, after systemic
F-PMO delivery in 4 week mdx mice (400mg/kg, n= 3). Co-localization of
PMO and MYH3+ve myofibers examined in gastrocnemius, quadriceps, and
triceps at 24 and 72 h post-PMO delivery. Asterisks denote fiber identity
between serial cross-sections; arrowheads denote examples of MYH3+ve
myofibers with nuclear PMO. Dashed boxes show magnified inlay; scale bars
represent 50 μm. b Quantification of PMO localization in MYH3+ve
myofibers shown as percent of labeled fibers. Statistical analysis performed
by Mann–Whitney nonparametric test; ***p< 0.001. Data represented as
scatter plot with SD
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correlate with the intensity of muscle pathology and to localize to
lesions elicited by myotoxin injection29. Here, we further clarify this
association by tying the level of exon skipping induced by
systemically administered PMO to coincident myofiber regenera-
tion and inflammatory exudation; two temporally linked but
mechanistically separable features of muscular dystrophy pathology.
Gross pharmacokinetic analysis paints a picture in which ~90%
of systemically delivered PMO is eliminated from the blood
within the first hour, reaching baseline serum levels within 3 h
and leaving barely detectable traces within muscle tissue25–28.
This underlies a widely accepted view that entry into muscle
fibers is limited to those that were in a susceptible state during
this short period of systemic availability. Our analysis of PMO
uptake at the cellular level transforms this model. First, it
identifies the route of PMO into muscle fibers, whereby myogenic
precursors mediate direct delivery into regenerating myofibers.
Second, it implicates the inflammatory response, and macro-
phages in particular, as drug repositories that maintain PMO
availability to myogenic cells for several days after its dis-
appearance from the blood.
Our evidence identifies myogenic precursors as vehicles of direct
delivery of PMO into regenerating myofibers. Shortly after
administration F-PMO is observed in regenerating lesions within
active (PAX7+ve) and differentiating (MYOG+ve) satellite cells, and
later, within adjacent immature myotubes. It is also possible that
entry occurs directly during the myoblast fusion process. Such a
succession suggests a mechanism whereby cells lying in
inflammatory and regenerating foci are readily penetrated by PMO,
and cells committed to myogenesis mediate PMO entry into
myofibers during the process of repair. This is in line with our
observations in tissue culture where PMO entry was only margin-
ally detectable in proliferating myoblasts, but became readily mea-
surable during differentiation and yet more so, during fusion.
The overall strength of our case for the central role of
myogenic cells in vivo comes from the use of “BrdU birthdating”
of muscle fiber nuclei. This provides a common point of reference
between penetration of F-PMO, occurrence of exon skipping, and
production of dystrophin protein. Thus, the most conspicuous
F-PMO penetration of differentiating myogenic cells occurred in
those lesions that had undertaken the bulk of their proliferation
during the previous 3 days. It was almost exclusively these same
BrdU+ve cells that subsequently gave rise to dystrophin-expres-
sing muscle fibers, while the myogenic cells that had been
proliferating more than 4 days earlier yielded only a minority of
fibers that were penetrated by F-PMO and went on to produce
dystrophin. Moreover, the sustained persistence of PMO in dys-
trophic lesions accounts for the unexpected finding of double-
labeled dystrophin+ve/BrdU+ve cells when BrdU was provided
after the administration of PMO.
Our observations also identify inflammatory macrophages as a
reservoir for prolonged availability of PMO to regenerating muscle
fibers. Direct visual tracking of intravenously injected
F-PMO revealed its persistence in localized patches, correspond-
ing to areas of muscle damage, regeneration, and inflammation,
a
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Fig. 6 Robust PMO uptake in actively regenerating myofibers concurrent with systemic PMO delivery. a Myonuclear PMO uptake after single IV dose of
F-PMO (400mg/kg, n= 3) in 4 week mdx mice treated with staggered pulses of BrdU (refer to Fig. 1c “PMO uptake”). Note, asterisks denote fiber identity
between serial cross-sections and arrowheads denote examples of centrally-nucleated BrdU+ve/PMO+ve myofibers. Venn diagrams demonstrate the
overlap between F-PMO localization (PMO+ve) and myofiber regeneration (BrdU+ve). Scale bars represent 50 μm. b Quantification of PMO+ve/BrdU+ve,
PMO+ve/BrdU−ve, and PMO−ve/BrdU+ve myofibers shown as percent of labeled fibers per BrdU cohort (n= 3 mice per cohort). Statistical analysis
performed by Mann–Whitney nonparametric test; ***p< 0.001, **p< 0.01, *p< 0.05. Data represented as scatter plot with SD
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for several days after its disappearance from the blood. Within
these foci, diffuse PMO signal was visualized within interstitial
spaces; however, the most robust signals were intracellular, within
the myonuclei of small-diameter, newly formed, immature myo-
fibers, and also within infiltrating inflammatory cells, a large
proportion of which were macrophages.
Productive entry of PMO into muscle requires that the drug
escape from the microvasculature into the interstitial space of
inflammatory lesions generated by muscle fiber necrosis, putting it
in intimate contact with susceptible cells of regenerating muscle.
However, entry of PMO by equilibration across the inflamed
microvascular bed should also predispose toward its loss in concert
with the rapid drop in serum concentration, whereas we observed
persistence of PMO for several days in inflamed sites. For such
sustained PMO retention, the macrophage population is a clear
suspect. Visually these cells form the main repository of F-PMO in
these lesions in vivo. Furthermore, in culture, macrophages show
avid PMO uptake and subsequent release of more than half of their
PMO content over the following several days. Thus, they are cap-
able of fulfilling a role as the persisting local source of PMO not in
simple equilibrium with the serum, thereby acting to extend the
duration of local drug availability. The question of whether all of the
PMO is acquired while the macrophages reside within inflamed
sites or whether some is actually phagocytosed in the blood and
carried into the lesions is also of interest and suggests strategies for
improving the efficiency of PMO delivery. Certainly, the chemical
stability of PMO41, 42 would fit well with a schema whereby
macrophages act as a buffering reservoir. Whether the release from
macrophages is direct or via exosomes is also a topic of our future
exploration. Likewise, the well-attested influence of macrophages on
myogenic cell function via an array of cytokine interactions43–50
prioritizes examination of their role together with other compo-
nents of the inflammatory environment51–53. Although intramus-
cular injection of PMO was found to induce strong levels of exon
skipping11, 12, 19, this route of administration directly introduces
local high concentrations of PMO into the interstitium rendering
the exudative inflammatory component of our mechanism largely
redundant; further, it adds mechanical damage and hydraulic
expansion of the endomysial space. Together, this may account for
the more impressive results seen in the first clinical trials that uti-
lized intramuscular delivery54 than in subsequent trials involving
systemic delivery20. An understanding of the dynamics of this
system is clearly important to any attempt to optimize PMO-
induced exon skipping in muscle.
We postulate that inflammatory foci act as local drug reservoirs
for several days after the PMO had been eliminated from the
circulation. Within these foci, PMO would have unimpeded
access to the newly forming myofibers via differentiating and
fusing myogenic precursors. Even at the high PMO doses we
employed, we saw no evidence of direct entry of PMO into
structurally intact extrafusal muscle fibers, nor did we observe
PMO entry into quiescent satellite cells remote from regenerating
muscle lesions. Thus, the nearly one-to-one relationship of
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Proliferating and differentiating satellite cells
Fig. 7 PMO infiltration of proliferating and differentiating myoblasts facilitates entry into actively regenerating fibers. a PMO uptake in proliferating
(PAX7+ve, top panel) or differentiating (MYOG+ve, bottom panel) myoblasts within regenerating foci. mdx mice treated at 4 weeks with a single dose of
F-PMO (400mg/kg, n= 3) and euthanized 24 h after PMO delivery. Asterisks denote fiber identity between serial cross-sections; arrowheads denote
PAX7+ve or MYOG+ve (green) cells co-labeled for PMO (red). Myoblasts void of PMO remain unmarked for comparison. Images acquired by confocal; dashed
boxes show magnified inlay and scale bars represent 50 μm. b PAX7+ve satellite cells residing in non-regenerating muscle regions do not co-localize with PMO+ve
nuclei. Arrowheads mark PMO+ve nuclei. Merged image shows PMO (red), PAX7 or MYOG (green), WGA (cyan), and DAPI (blue). Gastrocnemius shown; scale
bars represent 50 μm. c Schematic representation of myoblast proliferation, differentiation, and fusion with corresponding gene expression
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3 days prior to, or coincident with PMO delivery, suggests that
productive PMO entry into dystrophic muscle fibers occurs
via the regenerative process and argues against significant
involvement of other mechanisms.
The above picture does not fit well with recent reports of
successful exon skipping in the mdx mouse with chronic delivery
of much lower doses of PMO than we have used55. In one case
this was boosted by co-administration of PMO with hexoses,
suggesting that cellular uptake of PMO occurs via an energy-
dependent mechanism56. The main ATP requiring processes in
our model are the proliferation and fusion of myoblasts and the
phagocytic activity of macrophages, which are both difficult to
reconcile with acute changes in ATP levels. How these would fit
with our findings remains unclear but should be readily suscep-
tible to investigation within our experimental model.
Our revised view of the mechanisms underlying productive
PMO entry into muscle has direct implications for multi-exon
skipping strategies for DMD57. Multiple skipping requires
targeting of all components of an entire antisense cocktail to the
same single nascent dystrophin transcript within a substantial
proportion of myonuclei within individual myofibers; such
a scenario is difficult to reconcile with a mechanism of low
frequency, random, independent entry of each antisense compo-
nent into the musculature. Our identification of a mechanism that
would concentrate entry of all of the components of a PMO
cocktail synchronously into a localized, punctate site via the repair
process, provides a plausible rationale for this approach in DMD.
Methods
Animal studies. All animal procedures were thoroughly reviewed and given
explicit prior approval by the Institutional Animal Care and Use Committee of
Children’s National Health System (CNHS) in Washington DC. The C57Bl/
10ScSn-mdx/J mouse model of DMD (mdx) was utilized for all experiments and
harbors a nonsense point mutation in exon 23 of the dystrophin gene, thereby
abolishing dystrophin protein expression58. The C57Bl/10ScSnJ (Bl10 or wild-type)
mouse was used as the control where indicated. mdx and Bl10 mice ages 3 weeks to
4 months old were used in the various studies. Mouse strains were initially obtained
from the Jackson Laboratory (Bar Harbor, ME). Mice were housed and bred at the
CNHS Research Animal Facility, provided food, water and enrichment ad libitum,
and maintained under 12 h light/dark cycles.
Tissue harvesting and cryosectioning. Mice were euthanized at designated time
points following drug administration via CO2 inhalation and cervical dislocation.
Muscle samples including tibialis anterior, extensor digitorum longus, quadriceps,
gastrocnemius, triceps, biceps, diaphragm, and heart were surgically removed,
mounted on cork with tragacanth gum, flash-frozen in liquid nitrogen-chilled
isopentane and stored at −80 °C. For immunohistochemistry, tissues were sec-
tioned at 8 μm on a Leica CM1900 cryostat and stored at −80 °C; serial sections
were utilized where indicated due to incompatible immunohistochemistry tech-
niques or reagents.
PMO antisense sequences and delivery. PMO targeting the exon-intron
boundary of exon 23 of the dystrophin pre-mRNA (+7–18; 5′-GGCCAAACC
TCGGCTTACCTGAAAT-3′)12, 35, 36 were synthesized (GeneTools, OR). A
modified PMO23 oligo conjugated to fluorescein (+7–18; 5′-GGCCAAACCTC
GGCTTACCTGAAAT-3′-Fluorescein) was also used to track the delivery and
localization of the drug. PMO was diluted in saline and warmed at 50 °C for 15 min
prior to injection. Mice were anesthetized with 4% isofluorane and PMO was
administered systemically via the retro-orbital sinus as a single 200–800 mg/kg
dose (<300 μl total volume) using a 31-guage/0.3 mL insulin syringe. Saline was
ca
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Fig. 8 In vitro assessment of PMO uptake during myoblast differentiation and fusion. a F-PMO uptake in H2k-mdxmyoblasts and fusing myotubes in vitro after
a 24 h treatment with 100 μM F-PMO. F-PMO (red), actin (green), DAPI (blue). b Quantified F-PMO uptake (pmol) in H2k-mdx myoblasts at the designated
time points pre-differentiation and post-differentiation after treatment with 100 μM F-PMO. c Exon skipping quantified by RT-qPCR as relative level of skipped
vs. unskipped Dmd transcript 24 h following a 3 or 24 h F-PMO treatment (100 μM). Data represented as mean with SD. DM denotes change to differentiation
media. d DIC imaging of H2k-mdxmyoblasts at time points after onset of differentiation when seeded at optimal density to promote efficient myoblast fusion, or
low density to inhibit myoblast fusion. eQuantified F-PMO uptake (pmol) in H2k-mdx cells treated with F-PMO (100 μM, 24 h) 2 days post-differentiation when
maintained at optimal or low density. f Dmd mRNA transcript copy number quantified by RT-qPCR for skipped and unskipped transcripts 24 h after F-PMO
treatment (100 μM, 24 h) in response to myoblast differentiation and fusion. Data represented as bar graph or scatter plot with SD. Statistical analysis
performed by one-way ANOVA (b, c) or Mann–Whitney nonparametric test (e, f), ***p<0.001, **p<0.01, *p<0.05. Scale bars represent 50 μm
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injected at equivalent volumes as a control. Mice were euthanized at the designated
time points indicated throughout the study.
BrdU administration. 5′-bromo-2′-deoxyuridine or BrdU (Sigma-Aldrich, MO)
was administered ad libitum in drinking water at a concentration of 0.8 mg/ml for a
period of 24–72 h. BrdU was prepared in sterile water and kept protected from light
during administration. For BrdU pulse-labeling studies, BrdU was administered
from 21 to 24 days (72 h), 24 to 27 days (72 h), 28 to 31 days (72 h) in conjunction
with a single high dose of PMO delivered on the morning of day 28 coincident with
BrdU administration for the 28–31 days cohort.
Immunohistochemistry. Cryosections were stained with anti-dystrophin
(GTX15277, 1:100, GeneTex, CA), anti-fluorescein (A889, 1:200, Life Technologies,
MA), anti-BrdU-biotin conjugate (B35138, 1:100, Life Technologies, CA), anti-
laminin-α2 (4H8-2, 1:100, Enzo, NY), anti-laminin (L9393, 1:400, Sigma-Aldrich,
MO), anti-embryonic myosin heavy chain (MYH3) (F1.652, 1:25, Developmental
Studies Hybridoma Bank, University of Iowa), anti-PAX7 (PAX7 concentrate, 1:20,
Developmental Studies Hybridoma Bank, University of Iowa), anti-myogenin
(sc12732, 1:100, Santa Cruz, TX), and F4/80 (CI-A3-1, 1:40, AbD Serotec, NC).
Sections were fixed in ice-cold acetone for 10min, washed in PBS (0.1% tween-20),
and blocked for 1 h in PBS supplemented with 20% goat serum (GeneTex, CA),
0.1% tween-20 (Sigma-Aldrich, MO), and 10mg/ml BSA (Sigma-Aldrich, MO).
Primary antibodies were incubated overnight at 4 °C in a humidified chamber.
Sections were then washed and probed with the appropriate Alexa Fluor secondary
antibody (Life Technologies, MA) at a dilution of 1:500 for 1 h at room
temperature. Wheat germ agglutinin (WGA) conjugated to Alexa Fluor 488, 568, or
647 (Life Technologies, MA) was prepared as 1 mg/ml stock solutions and used at a
1:500 dilution in PBS. Sections were mounted with Prolong Gold Mounting Media
(Life Technologies, MA) with DAPI for nuclear staining if necessary. To probe for
the F-PMO, fixation was performed in 4% paraformaldehyde for 10 min at room
temperature; secondary Alexa Fluor 568 was utilized to exclude low-level fluores-
cence emitted by the fluorescein tag. For BrdU immunostaining, sections were fixed
in ice-cold acetone for 10min, incubated in 2 N HCl at 37 °C for 30min, and briefly
neutralized with 0.15M sodium tetraborate (Sigma-Aldrich, MO); sections were
blocked and incubated in the appropriate antibodies as described above.
Microscopy. Microscopy was performed using an Olympus BX61 VS120-S5
Virtual Slide Scanning System with UPlanSApo 40×/0.95 objective, Olympus
XM10 monochrome camera, and Olympus VS-ASW FL 2.7 imaging software.
Additionally, images were acquired using an Olympus FV1000 Confocal
Microscope with UPlanFLN 40×/1.30 oil objective and Olympus FV-ASW ver-
sion 4.2 imaging software. Live cell culture imaging was performed using an
Olympus IX81 with LUCPlan FLN 20×/0.45 objective, Olympus XM10 mono-
chrome camera and Olympus CellSens 1.13 software. Analysis and quantification
were performed using Olympus CellSens 1.13, MetaMorph Premier 7.7.0.0, Adobe
Photoshop CS6, and ImageJ software.
PMO/dystrophin and BrdU co-localization quantification. Quantification of
PMO/dystrophin and BrdU co-localization was performed on gastrocnemius, tri-
ceps, and quadriceps of mdx mice treated as described above. Regions were selected
based primarily on clustered PMO at 4 days or dystrophin immunostaining at
14 days post PMO administration. Average fiber number per region was ~85 fibers
for PMO-BrdU immunostained tissue and ~175 fibers per region for dystrophin-
BrdU immunostained tissue. Regions of early regeneration and/or severe inflam-
mation were not included in quantification if a discernable fiber membrane was
lacking (i.e., diameter <10 μm) for a given PMO+ve or BrdU+ve nucleus. Gastro-
cnemius, triceps, and quadriceps were analyzed (n= 3 mice per treatment cohort).
For PMO-BrdU quantification, serial cross-sections were utilized due to incom-
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Fig. 9 Investigation of PMO uptake and release in cultured macrophages.
a F-PMO uptake in cultured RAW 264.7 macrophages (Mφ) after 24 h
treatment with 100 μM F-PMO. F-PMO (red), DAPI (blue). Arrowheads
mark PMO+ve macrophages. Scale bar represents 20 μm. b Quantified
F-PMO uptake (pmol) in cultured macrophages at designated time points
after 24 h treatment of 10, 100, and 250 μM F-PMO. c Release of F-PMO
(pmol) from cultured macrophages quantified at 0.5, 24, 48, and 72 h after
24 h F-PMO treatment (0, 10, 100, or 250 μM). d Normalized CCK-8
viability assay for cultured macrophages 24, 48, and 72 h, after 24 h
PMO treatment. Statistical analysis performed by one-way ANOVA,
***p< 0.001, **p< 0.01, *p< 0.05
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PMO 800 mg/kg PMO 200 mg/kgDys BrdU Dys BrdU
Fig. 10 Role of myofiber repair in productive exon skipping consistent
between low and high systemic PMO doses. a Dystrophin restoration and
BrdU co-localization observed in 4–6 week mdx mice (i.e., triceps,
gastrocnemius) after single, systemic dose of PMO (200 or 800mg/kg,
n= 3). BrdU administered for 72 h prior to IV PMO delivery. Dystrophin
(Dys, red) and BrdU+ve myonuclei (green) 14 days after PMO. Scale bars
represent 100 μm. b Quantification of dystrophin and BrdU co-localization
after 200 or 800mg/kg PMO shown as percent of labeled fibers.
c Quantification of dystrophin-expressing fibers after a single dose of
200 or 800mg/kg or 4 weekly 200mg/kg doses shown as percent of
total fibers per cross-section. Data represented as scatter plot with SD.
Statistical analysis performed by Mann–Whitney nonparametric test;
***p< 0.001, **p< 0.01, *p< 0.05
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PMO+ve/BrdU−ve, and PMO−ve/BrdU+ve or dystrophin+ve/BrdU+ve, dystrophin+ve/
BrdU−ve, and Dys−ve/BrdU+ve. Percentages were calculated based on total PMO/
dystrophin+ve and BrdU+ve fibers quantified per region per muscle.
TaqMan RT-qPCR. Total RNA was extracted from muscle biopsies using TRIzol
(Life Technologies, MA). Total RNA (400 ng) was reverse transcribed using the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA)
following the manufacturer’s protocol with one modification; the random primer
mix was replaced with forward (5′-CAGAATTCTGCCAATTCGTGAG-3′) and
reverse (5′-TTCTTCAGCTTGTGTCATCC-3′) primers amplifying exons 20–26
(Integrated DNA Technologies, IA). cDNA (10 ng) was loaded for each triplicate
reaction and analyzed using mouse-specific TaqMan probes (Life Technologies,
MA) on the 7900HT Fast Real-Time PCR system. The TaqMan gene expression
probe for the skipped product (Life Technologies Assay ID# AIOIXIL) was custom
designed to amplify the splice junction at exon 22–24. For the non-skipped product,
TaqMan gene expression probe (Life Technologies Assay ID# Mm0126935_m1)
was used to amplify the region spanning exons 23–24. Absolute quantitation of
muscle-specific gene expression was calculated using a standard curve derived from
a known quantity of DNA plasmids. The skipped product fragment (exon 22–24)
and the non-skipped product fragment (exon 23–24) were cloned separately into
pMA-T vectors (Life Technologies, MA), purified and concentrated. Percentage
exon skipping was calculated using the following equation: [Average of triplicate
reactions of skipped DMD/(Average of triplicate reactions of skipped DMD+
Average of triplicate reactions of non-skipped DMD)] × 100. Dmd skipped and
unskipped transcript copy number was calculated based on a standard curve and
represents transcript copy number per 10 ng extracted RNA. Additionally, Des
expression assessed using TaqMan gene expression probe Mm00802455_m1; Myh3
expression assessed using TaqMan gene expression probe Mm01332463_m1
(Life Technologies, MA); here, total RNA was reversed transcribed using a random
primer mix according to the manufacturer’s protocol (Applied Biosystems, CA).
Nested RT-PCR. Total RNA was isolated and reverse transcribed as described
above. Primary PCR using 350 ng of cDNA was carried out using the Platinum
TaqPCRx DNA Polymerase (Thermo Fisher, MA) with a hot start at 94 °C for
2 min, followed by 30 cycles of 95 °C (30 s), 55 °C (1 min), and 72 °C (2 min).
Approximately 20 ng of the primary PCR products were re-amplified using the
Platinum TaqPCRx DNA Polymerase (Thermo Fisher, MA) with forward
(5′-CCCAGTCTACCACCCTATCAGAGC-3′) and reverse (5′-CAGCCATC-
CATTTCTGTAAGG-3′) primers amplifying exons 20–24. The secondary PCR was
carried out with a hot start at 94 °C for 2 min, followed by 22 cycles of 95 °C (30 s),
55 °C (1 min), and 72 °C (2 min). Secondary PCR products were analyzed on a 2%
agarose gel to identify skipped and unskipped dystrophin transcripts.
Cell culture and PMO quantification. H2k-mdx myoblasts were maintained in
DMEM, high glucose (4500 mg/L), pyruvate (100 mg/L) and GlutaMAX (Life
Technologies, MA) supplemented with 20% heat inactivated FBS (Atlanta Biolo-
gicals, GA), 2% chick embryo extract (United States Biological) and 1% penicillin/
streptomycin (100 U/mL) (Life Technologies, MA) on 0.4% gelatin-coated plates.
Myoblasts were proliferated (5000 cells/cm2) at 33 °C with 10% CO2 and 20 ng/ml
of IFNγ (R&D Systems, MN). For differentiation, myoblasts (26,000 cells/cm2)
were plated onto 24-well 0.4% gelatin-coated plates; after 24 h the media was
aspirated and replaced with differentiation media (DM) containing DMEM, high
glucose (4500 mg/L), pyruvate (100 mg/L) and GlutaMAX supplemented with 5%
horse serum and 1% penicillin/streptomycin (100 U/mL) (Life Technologies, MA).
Cells were differentiated for up to 7 days at 37 °C with 5% CO2. To inhibit myotube
formation, myoblasts were seeded at 25% of optimal density (6500 cells/cm2) and
maintained under differentiation conditions. F-PMO was delivered to cultured cells
at concentrations of 10–500 μM for 3–72 h at the designated time points to assess
F-PMO uptake and exon skipping levels. Concentrations mimic the approximate
PMO concentration achieved after systemic PMO delivery (i.e., 400 mg/kg yields an
immediate systemic concentration ~500 μM, respectively, based on approximate
blood volume, which drops to ~50 μM within 1 h). RAW 264.7 macrophages
(ATCC, VA) were cultured in DMEM, high glucose (4500 mg/L), pyruvate
(100 mg/L) and GlutaMAX supplemented with 10% heat inactivated FBS and 1%
penicillin/streptomycin (100 U/mL) (Life Technologies, MA) at 37 °C with 5%
CO2. RAW intracellular F-PMO concentrations were estimated based on cell
density (3 × 106 cells per well) and approximate cell volume (1000 μm3). For all
assays, intracellular and released F-PMO was quantified by fluorescence intensity
on a fluorescent plate reader. Exon skipping levels were evaluated from purified
RNA extracted 24 h after PMO treatment during myoblast differentiation (change
from growth media to DM noted as day 0). Western blot analysis was performed to
confirm H2k cell differentiation during the PMO treatment time course; lysates
were collected at the conclusion of each 24 h PMO treatment and subsequently run
on NuPAGE Novex 3–8% tris-acetate protein gels (Thermo Fisher, MA) under
denaturing conditions. Antibodies against MYH3 (F1.652, 1:1000, Developmental
Studies Hybridoma Bank) and β-actin (sc-47778, Santa Cruz Biotechnology, TX)
were utilized. Cell viability was determined using trypan blue or CCK-8 viability
reagent (Sigma-Aldrich, MO) according to the manufacturer’s protocol.
Statistical analyses. Statistical comparisons were performed by Mann–Whitney
non-parametric rank sum test or one-way analysis of variance (ANOVA) test based
on statistical assumptions and normality of data distributions. Data are typically
reported as scatter plots ±SD. In all experiments, the differences were considered
statistically significant when p< 0.05 and was reported as follows: ***p< 0.001,
**p< 0.01, *p< 0.05.
Data availability. The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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